Cyberounds Logo
September 20, 2017 | LOGIN | REGISTER | HELP | 


email a friend print Bookmark and Share
The Role of B-Type Natriuretic Peptide and NT-proBNP in the Diagnosis and Management of Heart Failure
CME credit is no longer available for this conference.
Ali H. Shakir, M.D., Richard W. Smalling, M.D., Ph.D. and Rebecca R. Hung, M.D.

Dr. Shakir is a Fellow, and Dr. Hung is Assistant Professor and Associate Director of Heart Failure, Division of Cardiovascular Medicine, University of Texas Health Science Center, Houston, Texas.

Dr. Shakir reports no commercial conflict of interest. Dr. Hung has been a consultant to Scios and GSK and Dr. Smalling has received grant/research support from Centocor/Boston Scientific within the last three years.

This activity is made possible by an unrestricted educational grant from Roche Diagnostics Roche Diagnostics.


Release Date: 12/01/2003
Termination Date: 12/01/2006

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • List the physiologic properties of B-type natriuretic peptide (BNP) and NT-proBNP
  • Describe the utility and limitations of measuring plasma BNP and NT-proBNP levels in the diagnosis and management of congestive heart failure
  • Discuss the role of recombinant BNP (nesiritide) in the treatment of decompensated heart failure.

 
This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity